CORRECTION article

Front. Pharmacol., 21 November 2022

Sec. Integrative and Regenerative Pharmacology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1073510

Corrigendum: Pharmacological activity and clinical use of PDRN

  • 1. Section of Pharmacology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

  • 2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy

In the published article, the Conflict of Interest statement was incorrectly filed. Disclaimers on patents were omitted from the article. The correct Conflict of Interest statement appears below.

“Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB, and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease. Author LM is a co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

adenosine A2 receptors, DNA, oligonucleotides, PDRN, wound healing

Citation

Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2022) Corrigendum: Pharmacological activity and clinical use of PDRN. Front. Pharmacol. 13:1073510. doi: 10.3389/fphar.2022.1073510

Received

18 October 2022

Accepted

19 October 2022

Published

21 November 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Francesco Squadrito,

This article was submitted to Integrative and Regenerative Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics